Our intellectual property (IP) portfolio reflects the innovative work that we have carried out in the field of RNAi. Our IP captures chemical modifications that are necessary for the delivery of stable siRNA molecules, siRNA structures and particularly potent sequences, as well as effective delivery methods.
Our short interfering RNA (siRNA) molecules are designed to trigger the RNAi pathway and mediate the degradation of specific target messenger RNAs (mRNAs), resulting in the expression of a particular disease-causing gene being inhibited.
Our therapeutic siRNA molecules are combined with delivery systems which aim to markedly enhance the efficiency and specificity of our siRNA drugs by directing them to the right cell type in the body and sparing healthy tissues.
Partnerships & Collaborations
At Silence we are developing novel RNAi based therapies with the potential to transform patients’ lives. Our proprietary technology platform is designed to intervene at the root of the problem by targeting the expression of disease-causing genes.
We envisage partnerships with pharmaceutical and biotechnology companies, as well as leading academic institutions, as an essential component of our product development strategy. We are committed to creating collaborations that maximise value for each of our partners.